Paraganglioma are rare neuroendocrine tumors that develop from chromaffin cells located near the adrenal glands or along the sympathetic and parasympathetic nervous systems. These tumors can be non-functional and functional, functional paraganglioma may secrete catecholamines and lead to hypertension if not treated timely. Surgery is the mainstay treatment for paraganglioma as it aims to remove the entire tumor while limiting damage to nearby nerves and blood vessels. Other treatment options include radiation therapy, chemotherapy, embolization or ablation.
The Paraganglioma Market is estimated to be valued at USD 366.2 Mn in 2024 and is expected to reach USD 412.5 Mn by 2031, growing at a compound annual growth rate (CAGR) of 1.7% from 2024 to 2031.
Key Takeaways
Key players operating in the Paraganglioma Treatment are Eli Lilly and Company, Pfizer Inc., Direct Therapeutics.
Key opportunities in the market include increasing investment by pharmaceutical companies in developing drugs with minimal side effects. Growing awareness about early diagnosis and treatment of paraganglioma tumors also presents lucrative opportunities.
The market is witnessing significant expansion in regions such as North America, Europe, Asia Pacific due to improving healthcare infrastructure and increasing patient access to advanced treatment options.
Market drivers
Increasing healthcare expenditure is one of the major drivers of Paraganglioma Market. Rising disposable incomes have enabled people to spend more on their health through private and public insurance. This has boosted demand for sophisticated diagnostic techniques and effective treatment regimens for rare conditions such as paraganglioma. Growing medical insurance penetration will further propel the market during the forecast period.
PEST Analysis
Political: The healthcare reforms and regulations by governments across the globe impact the market. Regulations regarding drug approval and procedures affect treatment options.
Economic: Rising healthcare expenditures and increasing affordability for advanced treatments aid market growth. The economic stability and disposable income levels determine demand.
Social: Growing awareness about rare cancers and availability of support groups influence people to seek proper treatment. Changing lifestyles and dietary patterns affect the disease occurrence.
Technological: Developments in imaging technologies improve detection and diagnosis. Advancements in targeted drug therapies and minimally invasive surgery techniques provide better treatment outcomes.
Regions where market is concentrated in terms of value
North America accounts for the largest share globally, owing to developed healthcare infrastructure, high expenditure on rare cancer treatment, and favorable reimbursement policies. The availability of advanced therapies and presence of key players in countries like the US and Canada boost the regional market.
Fastest growing region
Asia Pacific is poised to grow at the fastest pace during the forecast period. This can be attributed to increasing healthcare expenses, raising awareness about rare cancers, and improving access to advanced treatments. Moreover, the growing geriatric population, which is at high risk of paraganglioma, and expanding private healthcare sector contribute to the regional market growth.
Author Bio:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.
(https://www.linkedin.com/in/money-singh-590844163)
a